Knights of Columbus Asset Advisors LLC Acquires 92,552 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Knights of Columbus Asset Advisors LLC increased its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 99.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 185,845 shares of the biopharmaceutical company's stock after acquiring an additional 92,552 shares during the period. Knights of Columbus Asset Advisors LLC owned approximately 0.14% of Halozyme Therapeutics worth $6,869,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of HALO. Harvey Capital Management Inc. acquired a new position in Halozyme Therapeutics during the 4th quarter valued at about $5,918,000. Hsbc Holdings PLC increased its stake in Halozyme Therapeutics by 35.0% during the 3rd quarter. Hsbc Holdings PLC now owns 78,404 shares of the biopharmaceutical company's stock valued at $3,006,000 after buying an additional 20,346 shares during the period. Allspring Global Investments Holdings LLC increased its stake in Halozyme Therapeutics by 174.5% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 887,274 shares of the biopharmaceutical company's stock valued at $33,894,000 after buying an additional 563,989 shares during the period. Aurora Investment Counsel acquired a new position in Halozyme Therapeutics during the 3rd quarter valued at about $1,347,000. Finally, Campbell & CO Investment Adviser LLC acquired a new position in Halozyme Therapeutics during the 3rd quarter valued at about $591,000. Institutional investors and hedge funds own 97.79% of the company's stock.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Wednesday, April 17th. The shares were sold at an average price of $38.49, for a total value of $384,900.00. Following the completion of the sale, the senior vice president now directly owns 168,176 shares in the company, valued at $6,473,094.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold 30,000 shares of company stock worth $1,196,800 over the last ninety days. 2.40% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

HALO has been the topic of several recent research reports. The Goldman Sachs Group lowered their price objective on shares of Halozyme Therapeutics from $45.00 to $40.00 and set a "neutral" rating on the stock in a research note on Thursday, January 18th. Morgan Stanley decreased their target price on shares of Halozyme Therapeutics from $61.00 to $59.00 and set an "overweight" rating for the company in a report on Tuesday, December 26th. Benchmark reiterated a "buy" rating and issued a $50.00 target price on shares of Halozyme Therapeutics in a report on Tuesday. StockNews.com upgraded shares of Halozyme Therapeutics from a "hold" rating to a "buy" rating in a report on Friday, February 23rd. Finally, TD Cowen began coverage on shares of Halozyme Therapeutics in a report on Thursday, February 29th. They issued an "outperform" rating and a $54.00 target price for the company. One analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $53.29.

Halozyme Therapeutics Stock Up 2.2 %

Shares of HALO stock traded up $0.83 during trading on Friday, hitting $38.64. 1,258,837 shares of the company were exchanged, compared to its average volume of 1,271,537. The company has a debt-to-equity ratio of 17.89, a quick ratio of 5.50 and a current ratio of 6.64. The firm has a market capitalization of $4.91 billion, a price-to-earnings ratio of 18.31, a P/E/G ratio of 0.44 and a beta of 1.25. The business's 50-day simple moving average is $39.56 and its 200 day simple moving average is $37.77. Halozyme Therapeutics, Inc. has a twelve month low of $29.85 and a twelve month high of $45.00.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing the consensus estimate of $0.77 by ($0.02). The company had revenue of $230.04 million for the quarter, compared to analyst estimates of $235.25 million. Halozyme Therapeutics had a return on equity of 248.20% and a net margin of 33.96%. As a group, analysts forecast that Halozyme Therapeutics, Inc. will post 3.45 EPS for the current fiscal year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.